(Total Views: 375)
Posted On: 02/24/2021 2:49:10 PM
Post# of 36564
certainly the excellent news today did not arouse interest. Why? perhaps because there are 21 vaccines in phase 3 and an increasingly large number in phase 1/2? ,
even considering the li-key vaccine the absolute best (and I have no doubt that it probably will), the considerable lag we have accumulated compared to competitors, and the large number of companies that are venturing into the formulation of vaccines, we it is penalizing: only with exciting phase 1/2 data maybe interest will focus on us.
But even without considering the vaccine, our underestimation is so obvious: only the over 64 million Ngio shares at a minimum of $ 5 for the imminent (I hope) listing, will give us almost $ 3 per Gnbt share.
And Ngio's 500 million valuation, I don't think they include any positive vaccine results ..
even considering the li-key vaccine the absolute best (and I have no doubt that it probably will), the considerable lag we have accumulated compared to competitors, and the large number of companies that are venturing into the formulation of vaccines, we it is penalizing: only with exciting phase 1/2 data maybe interest will focus on us.
But even without considering the vaccine, our underestimation is so obvious: only the over 64 million Ngio shares at a minimum of $ 5 for the imminent (I hope) listing, will give us almost $ 3 per Gnbt share.
And Ngio's 500 million valuation, I don't think they include any positive vaccine results ..
(3)
(0)
